KPC-Producing klebsiella pneumoniae strains that harbor AAC(6')-

Derek N. Bremmer; Cornelius J. Clancy; Ellen G. Press; Reem Almaghrabi; Liang Chen; E. Yohei Doi; M. Hong Nguyen; Ryan K. Shieldsb

doi:10.1128/AAC.03831-14

KPC-Producing klebsiella pneumoniae strains that harbor AAC(6')-

Derek N. Bremmer
, Cornelius J. Clancy
, Ellen G. Press
, Reem Almaghrabi
, Liang Chen
, E. Yohei Doi
, M. Hong Nguyen
, Ryan K. Shieldsb

Research output: Contribution to journal › Article › peer-review

20 Citations (Scopus)

Abstract

The aminoglycoside-modifying enzyme AAC(6')-Ib is common among carbapenem-resistant Klebsiella pneumoniae (CR-Kp) strains. We investigated amikacin (AMK) activity against 20 AAC(6')-Ib-producing CR-Kp strains. MICs clustered at 16 to 32 μg/ml. By the time-kill study, AMK (1× and 4×the MIC) was bactericidal against 30% and 85% of the strains, respectively. At achievable human serum concentrations, however, the majority of strains showed regrowth, suggesting that AAC(6')-Ib confers intermediate AMK resistance. AMK and trimethoprim-sulfamethoxazole (TMP-SMX) were synergistic against 90% of the strains, indicating that the combination may overcome resistance.

Original language	English
Pages (from-to)	7597-7600
Number of pages	4
Journal	Antimicrobial agents and chemotherapy
Volume	58
Issue number	12
DOIs	https://doi.org/10.1128/AAC.03831-14
Publication status	Published - 01-12-2014
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/AAC.03831-14

Cite this

@article{fdf37b443c2e4cb69de5f65989199e03,

title = "KPC-Producing klebsiella pneumoniae strains that harbor AAC(6')-",

abstract = "The aminoglycoside-modifying enzyme AAC(6')-Ib is common among carbapenem-resistant Klebsiella pneumoniae (CR-Kp) strains. We investigated amikacin (AMK) activity against 20 AAC(6')-Ib-producing CR-Kp strains. MICs clustered at 16 to 32 μg/ml. By the time-kill study, AMK (1× and 4×the MIC) was bactericidal against 30\% and 85\% of the strains, respectively. At achievable human serum concentrations, however, the majority of strains showed regrowth, suggesting that AAC(6')-Ib confers intermediate AMK resistance. AMK and trimethoprim-sulfamethoxazole (TMP-SMX) were synergistic against 90\% of the strains, indicating that the combination may overcome resistance.",

author = "Bremmer, \{Derek N.\} and Clancy, \{Cornelius J.\} and Press, \{Ellen G.\} and Reem Almaghrabi and Liang Chen and Doi, \{E. Yohei\} and Nguyen, \{M. Hong\} and Shieldsb, \{Ryan K.\}",

note = "Publisher Copyright: {\textcopyright} 2014 American Society for Microbiology. All Rights Reserved. This project was supported by the National Institutes of Health through grant no. KL2TR000146 awarded to R.K.S. and by the University of Pittsburgh Medical Center XDR Pathogen Laboratory.",

year = "2014",

month = dec,

day = "1",

doi = "10.1128/AAC.03831-14",

language = "English",

volume = "58",

pages = "7597--7600",

journal = "Antimicrobial agents and chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "12",

}

TY - JOUR

T1 - KPC-Producing klebsiella pneumoniae strains that harbor AAC(6')-

AU - Bremmer, Derek N.

AU - Clancy, Cornelius J.

AU - Press, Ellen G.

AU - Almaghrabi, Reem

AU - Chen, Liang

AU - Doi, E. Yohei

AU - Nguyen, M. Hong

AU - Shieldsb, Ryan K.

N1 - Publisher Copyright: © 2014 American Society for Microbiology. All Rights Reserved. This project was supported by the National Institutes of Health through grant no. KL2TR000146 awarded to R.K.S. and by the University of Pittsburgh Medical Center XDR Pathogen Laboratory.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - The aminoglycoside-modifying enzyme AAC(6')-Ib is common among carbapenem-resistant Klebsiella pneumoniae (CR-Kp) strains. We investigated amikacin (AMK) activity against 20 AAC(6')-Ib-producing CR-Kp strains. MICs clustered at 16 to 32 μg/ml. By the time-kill study, AMK (1× and 4×the MIC) was bactericidal against 30% and 85% of the strains, respectively. At achievable human serum concentrations, however, the majority of strains showed regrowth, suggesting that AAC(6')-Ib confers intermediate AMK resistance. AMK and trimethoprim-sulfamethoxazole (TMP-SMX) were synergistic against 90% of the strains, indicating that the combination may overcome resistance.

AB - The aminoglycoside-modifying enzyme AAC(6')-Ib is common among carbapenem-resistant Klebsiella pneumoniae (CR-Kp) strains. We investigated amikacin (AMK) activity against 20 AAC(6')-Ib-producing CR-Kp strains. MICs clustered at 16 to 32 μg/ml. By the time-kill study, AMK (1× and 4×the MIC) was bactericidal against 30% and 85% of the strains, respectively. At achievable human serum concentrations, however, the majority of strains showed regrowth, suggesting that AAC(6')-Ib confers intermediate AMK resistance. AMK and trimethoprim-sulfamethoxazole (TMP-SMX) were synergistic against 90% of the strains, indicating that the combination may overcome resistance.

UR - https://www.scopus.com/pages/publications/84912101206

UR - https://www.scopus.com/pages/publications/84912101206#tab=citedBy

U2 - 10.1128/AAC.03831-14

DO - 10.1128/AAC.03831-14

M3 - Article

C2 - 25288089

AN - SCOPUS:84912101206

SN - 0066-4804

VL - 58

SP - 7597

EP - 7600

JO - Antimicrobial agents and chemotherapy

JF - Antimicrobial agents and chemotherapy

IS - 12

ER -

KPC-Producing klebsiella pneumoniae strains that harbor AAC(6')-

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this